DrugPatentWatch Database Preview
Patent: 10,023,917
Summary for Patent: 10,023,917
| Title: | High resolution melting analysis as a prescreening tool |
| Abstract: | Compositions and methods for determining an increased likelihood of a response to a targeted treatment of a cancer disease including isolating genomic DNA from a patient sample, amplifying a fragment of DNA by means of PCR with a specific pair of amplification primers, determining if the amplified fragment comprises a wildtype sequence or a mutation by means of a High Resolution Melting Analysis (HRM), and correlating the presence or absence of a mutation with an increased likelihood of success of said targeted treatment. Respective primer pairs, compositions and kits are also claimed. |
| Inventor(s): | Buettner; Reinhard (Villiprott, DE), Froehner; Stefanie (Penzberg, DE), Merkelbach-Bruse; Sabine (Aachen, DE), Ney; Jasmin (Wallerfangen, DE), Roesler; Angelika (Sindelsdorf, DE) |
| Assignee: | Roche Molecular Systems, Inc. (Pleasanton, CA) |
| Application Number: | 14/958,567 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,023,917
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 003 | 2006-09-27 | ⤷ Try it Free | Roche Molecular Systems, Inc. (Pleasanton, CA) | 2031-01-11 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 002 | 2006-09-27 | ⤷ Try it Free | Roche Molecular Systems, Inc. (Pleasanton, CA) | 2031-01-11 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | ⤷ Try it Free | Roche Molecular Systems, Inc. (Pleasanton, CA) | 2031-01-11 | RX | search | |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | ⤷ Try it Free | Roche Molecular Systems, Inc. (Pleasanton, CA) | 2031-01-11 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,023,917
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2012095378 | ⤷ Try it Free |
| United States of America | 2014017682 | ⤷ Try it Free |
| United States of America | 2015152510 | ⤷ Try it Free |
| United States of America | 2016083804 | ⤷ Try it Free |
| United States of America | 8980556 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
